Oblique Therapeutics Secures SEK 14.1 Million in Rights Issue

The offering resulted in the issuance of 7,025,060 new shares at a price of SEK 2.00 each, an increase over the SEK 1.50 price point seen in the company's 2025 financing round. This expansion brings the total share count to 63,322,319, resulting in an 11 percent dilution for shareholders who opted not to participate. Once the Swedish Companies Registration Office processes the filing, interim shares will convert into ordinary equity.

CEO Christer Nordstedt noted that the successful raise serves as a validation of the firm's strategic direction. The proceeds are earmarked for advancing the company’s proprietary AbiProt technology, a platform designed to generate antibodies for difficult drug targets. Chairman Hans Peter Ostler stated that the fresh funding will bolster the development of the firm's project portfolio and support ongoing external collaborations. Eminova Fondkommission AB served as the issuing agent for the transaction.